ArticleEndocrinology2025
Oxytocin Attenuates the Endocrine Disrupting Effects of Cocaine in the Female Rat.
Article in Endocrinology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Endocrine modulation of stimulant use: bidirectional interactions within the hypothalamic-pituitary-gonadal axis.Frontiers in behavioral neuroscience · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
backgroundCurrent research indicates that women may exhibit greater susceptibility to cocaine use disorder. Cocaine's endocrine-disrupting effects, including acute impacts on gonadal hormones and chronic disruption of the estrous and menstrual cycles in rodents and humans, may contribute to this susceptibility; however, treatment options for endocrine dysfunction following cocaine exposure remain unexplored. We, and others, have highlighted oxytocin's (OXT) potential to mitigate cocaine use disorder-like behaviors, particularly in females.
methodsWe used female, intact and/or ovariectomized (OVX) Sprague-Dawley rats to investigate OXT's potential as a therapeutic agent for cocaine's acute and chronic endocrine disrupting effects. In acute studies, rats received OXT (0.3 mg/kg intraperitoneally, 30 minutes prior) or saline and cocaine (10 mg/kg intraperitoneally, 15 minutes prior) or saline before tail vein blood draw. In chronic studies (6 weeks), rats received cocaine or saline daily, and OXT or saline every 10 days to assess the effects of cocaine and OXT treatment on the estrous cycle. Serum samples were analyzed using enzyme-linked immunosorbent assays for progesterone (P4), estradiol (E2), and OXT levels.
resultsAcute cocaine spiked circulating P4 and E2, an effect that was mitigated by OXT pretreatment. Chronic cocaine administration decreased circulating P4 while increasing circulating E2 and significantly disrupted estrus cycling. Exogenous OXT restored P4 and E2 to precocaine baselines and similarly reversed concurrent effects on estrus cycle dysfunction.
conclusionOur results show that OXT may therefore act as a defense against cocaine-induced endocrine disruption, reducing its impact on estrous cycle instability. Thus, OXT is a potential treatment for the endocrine-disrupting effects of cocaine.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.